Find Academic Supervisors

• Pharmacometrics
• Population PKPD Modelling
• Clinical Pharmacology
• +4 more

Trine Meldgaard Lund serves as an Associate Professor in the Department of Drug Design and Pharmacology within the Faculty of Health and Medical Sciences at the University of Copenhagen. Her research focuses on optimizing pharmacotherapy and clinical trial designs through advanced pharmacometric modeling. With 85 research outputs and active collaborations across multiple countries, she maintains a significant international research presence. Her primary research domain centers on Population PKPD modelling and Pharmacometrics, specifically characterizing pharmacokinetic-pharmacodynamic relationships to identify sources of drug response variability. Key projects include fixed-dose combination development, model-based dose finding, PK meta-modeling of morphine, and investigating CYP enzyme differences in pediatric populations. Her work demonstrates strong translational impact through clinical pain trials and therapeutic drug monitoring applications. Lund's research portfolio shows consistent output in high-impact journals, with recent 2025 publications spanning nephrology, oncology, geriatric pharmacology, and cannabinoid therapeutics. Her work frequently addresses methodological challenges in clinical trial design and demonstrates particular expertise in modeling complex drug interactions and age-related pharmacokinetic variability. The collaborative nature of her research is evident through extensive co-authorship networks across Scandinavian institutions. As an educator, Lund teaches Pharmacokinetics and Pharmacodynamics across multiple courses including Basic Pharmacology, Principles of Pharmacology, and Organ-related Pharmacology. She also leads specialized elective courses and PhD-level instruction through the MIND program. Her academic leadership extends to organizing 9 significant professional activities including symposia on precision medicine, clinical trial design, and therapeutic drug monitoring for major Danish pharmacological societies.

Veronika WingstedtView profile

Researcher

• Nuclear Medicine
• Molecular Imaging
• Radiopharmaceutical Chemistry
• +3 more

Veronika Wingstedt serves as a Researcher within the Department of Medicinal Chemistry at Uppsala University, where she contributes to the Platform for Preclinical PET-MRI. Her technical expertise focuses on engineering advanced imaging protocols for biomedical research, specifically in the development and application of multimodal imaging techniques including PET, SPECT, and CT for preclinical disease modeling and drug evaluation. Her core research spans Nuclear Medicine , Molecular Imaging , and Radiopharmaceutical Chemistry , with specialized contributions in radiotracer synthesis (particularly C-11 and Ga-68 compounds), bone regeneration imaging, cancer theranostics, and endocrine disorder diagnostics. She integrates radiochemistry with molecular biology to develop imaging probes for bone morphogenetic protein tracking, insulinoma detection, and HER2-targeted prostate cancer therapy, emphasizing translational applications from preclinical validation to clinical feasibility studies. Analysis of her publication timeline (2012-2018) reveals consistent innovation in multimodal imaging probe development, with increasing focus on theranostic applications. Her work demonstrates methodological rigor in dosimetry calculations, radiolabeling optimization, and validation of imaging protocols across diverse disease models. Key thematic threads include the engineering of tri-modal visualization systems, precision targeting of molecular pathways in cancer, and quantitative assessment of physiological processes like cerebral blood flow during surgical interventions. No scientific awards, fellowships, or medals are documented in the provided materials. The available information does not specify graduate student advising relationships or external grant funding, though her extensive collaborative publication record indicates active participation in multidisciplinary research teams. As a core technical contributor to Uppsala University's Platform for Preclinical PET-MRI, Wingstedt supports biomedical research through state-of-the-art imaging infrastructure. This platform enables high-resolution quantitative studies across oncology, endocrinology, and bone disease research, with her engineering expertise directly enhancing capabilities in radiotracer development, multimodal imaging protocol design, and preclinical model validation.

• Computational Biology
• Cardiac Electrophysiology
• Systems Biology
• +4 more

David Gavaghan is a Professor of Computational Biology at the University of Oxford's Department of Computer Science, within the Mathematical, Physical and Life Sciences Division. He leads the Computational Biology Group and has held roles including Director of Graduate Studies in the Mathematical, Physical and Life Sciences Division and Chair of the Department's Equality and Diversity Committee. His research focuses on computational modeling of biomedical systems, particularly cardiac electrophysiology, tumor development, and electrochemical techniques. He has supervised over 30 PhD students and established the Life Science Interface Doctoral Training Programme, funded by £60 million in grants. Notable projects include the Chaste computational library and collaborations with industry partners like Microsoft Research and GSK. Research interests include interdisciplinary applications of mathematical and computational methods to biomedicine, with a focus on cardiac modeling, systems biology, and high-performance computing. He chairs the Chaste Users' Mailing List and has contributed to initiatives like the 2020 Science programme for computational natural scientists. His work emphasizes practical solutions for scientific challenges and has led to innovations in computational infrastructure and collaborative research frameworks such as the Virtual Physiological Human Toolkit. Professional activities include leadership in doctoral training, grants management, and gender equality initiatives. His contributions span academic and industrial collaborations, emphasizing the translation of computational models into real-world biomedical applications.

Adam DarwichView profile

Associate Professor

• Health Systems Engineering
• Healthcare Modeling and Simulation
• Pharmacokinetics
• +3 more

Adam Darwich is an Associate Professor in the Division of Health Informatics and Logistics at KTH Royal Institute of Technology. He is a Co-Principal Investigator (Co-PI) in the Data-driven Improvement of Work-Flows project at Karolinska University Hospital under the Digital Futures research center. His research focuses on modeling and simulation methods for healthcare decision-making, evidence generation for medical technologies, and real-world evidence (RWE) applications. He holds a PhD in Pharmaceutical Sciences and is a Licensed Pharmacist with expertise in pharmacokinetics and systems pharmacology. Research Interests: Dr. Darwich’s work integrates healthcare logistics, physiologically-based pharmacokinetic (PBPK) modeling, real-world data analysis, and health technology assessment. He leads projects on patient flow optimization, hospital overcrowding solutions, and precision dosing strategies. His contributions include developing frameworks for RWE generation and advancing methodologies for drug metabolism studies. Publications: His recent work emphasizes hybrid modeling approaches, machine learning applications in healthcare, and the use of real-world data to address discrepancies in clinical trial outcomes. Key topics include small cell lung cancer prognosis, biosimilar dosing optimization, and the impact of chronic kidney disease on drug clearance. Grants & Advising: As a Co-PI, he contributes to interdisciplinary grants focused on digital health innovation. He teaches courses on healthcare logistics, medical device design, and simulation methods in medical engineering at KTH. Labs & Teams: He is affiliated with the Center for Data Driven Health (CDDH) and collaborates with Digital Futures, a tripartite initiative with Stockholm University and RISE Research Institutes.

Zenong YinView profile

Professor

• Obesity Prevention
• Diabetes Management
• Public Health
• +4 more

Dr. Zenong Yin is a Professor in the College for Health, Community and Policy at The University of Texas at San Antonio, specializing in Public Health research. With a Ph.D. in Physical Education and Exercise Science from the University of Southern California, he focuses on culturally tailored lifestyle interventions for obesity and diabetes prevention across age groups. Ph.D., Physical Education and Exercise Science, University of Southern California M.A., Physical Education, University of Southern California Bachelor of Education, Physical Education, Beijing Institute of Physical Education, China His research integrates digital health technologies with randomized controlled trials to address health disparities among Mexican-American populations, particularly women and preschoolers. Recent work explores metabolomic responses to physical activity and technology-enhanced self-monitoring systems. Key trends in his publications include: digital health applications for weight management, culturally adapted interventions for underserved communities, and data-driven behavioral analysis in obesity prevention. Clinical trials like FE-SaLiR and Míranos! demonstrate his commitment to community-based health promotion. Y Living Family-Centered Diabetes Self-Management Program (2021-2024) Technology-assisted nutrition intervention for older adults ($1.18M, 2021-2024) Preschool obesity prevention studies (NCT03590834) MUJERES INTERESADAS EN CAMBIOS POR LA SALUD (MI CASA) grant Dr. Yin's work emphasizes health equity, with grants targeting Latino communities and older adults. His studies inform precision public health strategies through metabolomic profiling and behavioral feedback systems.

Mohd Hafiz Abdul-AzizView profile

Research Fellow

• Antimicrobial Pharmacokinetics/Pharmacodynamics
• Critical Care Medicine
• Extracorporeal Membrane Oxygenation
• +4 more

Dr. Mohd Hafiz Abdul-Aziz is a Research Fellow at the University of Queensland Centre for Clinical Research (UQCCR), affiliated with the Faculty of Health, Medicine and Behavioural Sciences. He leads the Clinical Dosing Studies and Knowledge Translation Workstream within the Antimicrobial Optimisation Group and the Centre for Research Excellence for Personalising Antimicrobial Dosing to Reduce Resistance (CRE RESPOND). Dr. Abdul-Aziz obtained his Bachelor of Pharmacy from the International Islamic University Malaysia (IIUM), a Master of Clinical Pharmacy from Universiti Kebangsaan Malaysia (UKM), and a PhD from the University of Queensland in 2016, focusing on pharmacokinetic/pharmacodynamic optimization of beta-lactam antibiotics in critically ill patients. His research centers on antimicrobial pharmacokinetics/pharmacodynamics (PK/PD) in critically ill populations, with specialized interests in: Dosing optimization for ECMO/RRT patients Prolonged beta-lactam infusions Therapeutic drug monitoring Ex-vivo pharmacokinetic modeling Multinational clinical PK studies He has authored over 80 peer-reviewed publications and book chapters, with work cited more than 4,800 times. Dr. Abdul-Aziz's recent publications demonstrate a strong focus on antimicrobial pharmacokinetics in extracorporeal support systems, beta-lactam optimization trials, and translational research in critical care pharmacotherapy. His studies frequently employ population PK modeling, multinational clinical trials, and ex-vivo experimental approaches to address dosing challenges in complex ICU populations. He has received significant recognition including: NHMRC Emerging Leadership Fellow EL2 (2026) Fellow of the International Society of Antimicrobial Chemotherapy (ISAC) He currently chairs the Infections in the ICU and Sepsis Working Group of ISAC. Dr. Abdul-Aziz leads multiple multinational pharmacokinetic studies including ASAP ECMO, BLING 3, and PNEUDOS. He actively collaborates with over 100 researchers across 36 countries and welcomes prospective postgraduate students interested in antimicrobial optimization research.

• Pharmacokinetics
• Pharmacodynamics
• Inflammation
• +5 more

Letao Li is a Researcher in the Pharmacy department at Erasmus MC, specializing in clinical pharmacology with focus on pharmacokinetics and pharmacodynamics in vulnerable patient populations. Affiliated with Rotterdam-based research teams, Li's work bridges pharmaceutical sciences and critical care medicine. Research interests center on drug behavior in inflammatory conditions, particularly examining how biomarkers like C-reactive protein alter pharmacokinetics in sepsis, pre-eclampsia, and pediatric oncology. Key themes include protein binding dynamics, glucocorticoid therapy optimization, and precision dosing for antibiotics in critically ill patients. Recent publications reveal strong emphasis on translating pharmacokinetic findings into clinical practice, with trends showing increasing focus on model-informed precision dosing (MIPD) frameworks. The work consistently addresses therapeutic challenges in high-risk groups including neonates, pregnant women, and sepsis patients. Key research areas: Pharmacokinetic alterations during inflammation Dexamethasone/betamethasone optimization in special populations Temocillin protein binding in critical illness Biomarker-guided dosing strategies Li's collaborative network spans multiple European institutions with significant work in pediatric oncology pharmacology and critical care pharmacotherapy. Current research appears focused on implementing precision dosing algorithms for vulnerable populations through model-informed approaches.

Farnoush Forghani-AraniView profile

Assistant Professor

• Radiation Oncology
• Medical Physics
• Adaptive Radiotherapy
• +5 more

Farnoush Forghani-Arani is an Assistant Professor of Radiation Oncology at Washington University School of Medicine in St. Louis, where they specialize in medical physics and radiation therapy techniques. Their work focuses on improving treatment planning and delivery for cancer patients, with particular expertise in adaptive radiotherapy for abdominal and thoracic malignancies. Education: PhD in Geophysics (minor in Mathematics) from Colorado School of Mines (2013) CAMPEP Certificate Program in Medical Physics from University of California, Los Angeles (2021) Postdoctoral Fellowship in Radiation Oncology at University of Colorado (2021) Medical Physics Residency at Washington University School of Medicine (2023) Dr. Forghani-Arani's research centers on advancing radiation therapy techniques through innovative imaging and dosimetry approaches. Their work bridges the gap between medical physics and clinical radiation oncology, with emphasis on developing more precise and personalized treatment strategies for cancer patients. They have made significant contributions to the understanding of functional lung imaging for radiotherapy planning and the application of advanced imaging techniques for pancreatic cancer treatment. Analysis of their publication record reveals a strong focus on adaptive radiotherapy techniques, particularly for challenging abdominal sites like pancreatic cancer where organ motion and proximity to critical structures present significant treatment challenges. Their work consistently addresses the integration of advanced imaging modalities (CBCT, MR, SPECT) with radiation delivery systems to improve treatment accuracy and patient outcomes. A recurring theme in their research is the development and validation of quality assurance methods for complex radiotherapy procedures. While specific mentoring activities aren't detailed in available information, their position as Assistant Professor suggests involvement in training medical physics residents and radiation oncology fellows. Their research program appears to be well-integrated with clinical practice at Washington University, focusing on translational applications of medical physics innovations. Their laboratory work likely involves collaboration with the medical physics team at Washington University's Siteman Cancer Center, utilizing state-of-the-art radiation therapy equipment including MR-guided and CBCT-guided treatment systems for developing and testing novel radiotherapy approaches.

• Geomatics
• Geographic Information Systems
• Satellite Navigation (GNSS)
• +7 more

Marco Piras is a Full Professor at the Department of Environmental, Land and Infrastructure Engineering (DIATI) at the Polytechnic University of Turin. He serves as Deputy Director of DIATI and a member of the Interdepartmental Center PIC4SeR for Service Robotics. His research focuses on geomatics, GIS, GNSS, photogrammetry, and UAV applications for environmental monitoring and infrastructure assessment. Research Interests: Geomatics and GIS for environmental applications Remote sensing and Earth observation Infrastructure monitoring using BIM and UAVs Climate change adaptation in flood-prone regions Machine learning in geospatial data analysis Scientific Awards: Licinio Ferretti Award (ASITA, 2009) Best ASITA Poster 2008 Grants & Collaborations: Coordinator of Framework Agreement with FAI (2022-2025) Member of Agreement with AGROINNOVA Competence Center (2021-2026) Lead in EU Horizon projects (AGRITech, ROCKtheAlps) Teaching: Courses in Geomatics, Statistical Data Processing, and Open Geospatial Data for Civil Engineering and Urban Development doctoral programs.

Michael NeelyView profile

Professor

• Pharmacometrics
• Bayesian Modeling
• Pediatric Infectious Diseases
• +4 more

Professor Michael Neely is affiliated with the Children's Hospital Los Angeles and the Keck School of Medicine at the University of Southern California. He is an internationally recognized expert in pharmacometrics and pediatric infectious diseases. Specializes in Bayesian modeling and individualized drug dosing for children Collaborated with Limoges University Hospital and Inserm U1248 on machine learning applications in pharmacometrics Focused on synthetic pharmacokinetic data generation and validation His visit to Limoges included seminars on "From In Silico to In Populo: Models Are Making the Difference" and "All About the p-Value", fostering interdisciplinary dialogue between clinical and computational approaches in pharmacology.

• Biostatistics
• Clinical Trials
• Precision Medicine
• +7 more

Bin Cheng serves as Professor of Biostatistics at Columbia University Medical Center, specializing in methodological innovations with applications across dental, neurological, and cardiovascular research domains. Education: BS, 1992, Shandong University MS, 1995, Institute of Mathematics, Chinese Academy of Sciences MA, 1999, State University of New York at Stony Brook PhD, 2004, University of Wisconsin at Madison His research program integrates adaptive trial designs and dose-finding methodologies with emerging fields like mobile health and precision medicine . Core technical expertise spans longitudinal data modeling , mixed-effects frameworks , and clustering algorithms , applied to critical areas including aging research and global health initiatives . This interdisciplinary approach bridges statistical theory with real-world clinical challenges through sustained collaborations with medical specialists. Scientific Awards: No scientific awards were mentioned in the provided text. Advising and Grants: The source material contains no information regarding doctoral students, postdoctoral trainees, or externally funded research grants associated with Dr. Cheng's work.

• Pharmacogenomics
• Pharmacoepidemiology
• Drug Response Genetics
• +7 more

Dr. Nita Limdi is a Professor and Associate Dean for Genomic Medicine at the University of Alabama at Birmingham (UAB) School of Medicine. She holds joint appointments in the Departments of Neurology, Epidemiology, and Pharmacology. Her research focuses on pharmacogenomics, particularly the genetic and environmental factors influencing drug response, with emphasis on anticoagulants and antiplatelet therapies. Dr. Limdi leads the Pharmacogenomics Implementation Program at the Hugh Kaul Personalized Medicine Institute, advancing clinical translation and overcoming barriers to genomic medicine adoption. She also chairs the Clinical Pharmacogenetics Implementation Consortium (CPIC) and collaborates with international consortia like the International Warfarin Pharmacogenetics Consortium (IWPC). Dr. Limdi’s work integrates clinical, genetic, and socio-demographic data to address health disparities, especially in African American populations. She oversees multidisciplinary teams across multiple UAB centers, including the Center for Outcomes and Effectiveness Research and Education (COERE) and the Comprehensive Neuroscience Center. Her leadership roles include serving as an Executive Leadership in Academic Medicine (ELAM) Fellow and member of the Healthcare Leadership Academy. Grant funding spans NIH initiatives in kidney research, cardiovascular pharmacotherapy, and translational science. Her teaching includes mentoring over 20 postdoctoral trainees and junior faculty in pharmacogenomics, clinical trials, and biostatistics. Key research themes include warfarin dosing genetics, polygenic risk scores for chronic diseases, and genomic implementation in diverse populations.

• Radiotherapy
• Oncology
• Epidemiology
• +5 more

Philip McLoone is an Honorary Research Fellow at the School of Health & Wellbeing, University of Glasgow. He is a statistician with epidemiological expertise, currently involved with the Radiotherapy Research Group at Beatson West of Scotland Cancer Centre in developing and appraising radiotherapy interventions and new methods of delivering treatment. His research interests span multiple areas of epidemiology and oncology, with a particular focus on: Radiotherapy applications in oncology Cancer epidemiology Cardiovascular epidemiology Socio-economic variations in health Use of health services in Scotland Public health statistics Analysis of his recent publications (2020-2024) reveals a strong focus on cancer treatment outcomes, particularly in radiotherapy applications across various cancer types. His work frequently examines treatment efficacy in specific patient populations, including elderly patients and those with comorbidities. There is also significant emphasis on methodological approaches in epidemiological research, with many studies utilizing large population datasets and registry information from Scotland. Dr. McLoone has collaborated extensively with researchers at the Beatson West of Scotland Cancer Centre and has contributed to numerous studies examining the relationship between cancer treatments and patient outcomes, with particular attention to radiotherapy techniques and their impact on survival and quality of life.

Zubida Al-MajdoubView profile

Research Fellow

• Pharmacology
• Pharmaco-omics
• Quantitative Proteomics
• +6 more

Zubida Al-Majdoub is a Research Fellow at The University of Manchester , affiliated with the Centre for Applied Pharmacokinetic Research (CAPKR) - a collaboration between academic researchers and nine industrial pharmaceutical companies. Her work bridges pharmacology, pharmaco-omics, and translational research through advanced quantitative proteomics and transcriptomics methodologies. Research interests focus on drug metabolism , transporter quantification , and pharmacokinetic modeling , with particular emphasis on blood-brain barrier dynamics and liquid biopsy technologies. She has pioneered exosome isolation from plasma for diagnostic/prognostic biomarker development, while maintaining strong industry/regulatory collaborations. Recent publications demonstrate expertise in multi-organ proteomics (liver, kidney, brain, placenta), in vitro-in vivo extrapolation , and precision dosing applications. Key innovations include QconCAT technology for protein quantification and LC-MS/MS workflows for drug target identification. Current CAPKR research activities incorporate physiologically based pharmacokinetic modeling , NFκB pathway modulation , and ABC transporter quantification across biological systems. She actively employs mass spectrometry imaging and systems pharmacology approaches to address real-world drug development challenges.

• Clinical Pharmacology
• Infectious Diseases
• Critical Care Medicine
• +3 more

Christina König is a researcher affiliated with the University of Hamburg's Medical Faculty. Her work focuses on clinical pharmacology, particularly antibiotic pharmacokinetics, drug interactions in critically ill patients, and antimicrobial resistance. She contributes to developing national guidelines, such as the German guideline for invasive pulmonary aspergillosis treatment. Her research addresses challenges in optimizing antibiotic dosing in specialized settings like intensive care units and extracorporeal membrane oxygenation (ECMO). She investigates drug behavior during renal replacement therapies and advanced organ support systems, ensuring effective antimicrobial delivery despite physiological stressors. König also explores drug-drug interactions, particularly in complex cases like severe infections and coronavirus disease (COVID-19) management. Her studies often involve collaborative, multi-center analyses and translational approaches to bridge pharmacology with clinical practice. Her research spans infectious diseases, including drug-resistant tuberculosis and fungal infections, alongside neurology-related infections like ventriculitis. She emphasizes therapeutic drug monitoring (TDM) for optimizing antibiotic efficacy and minimizing toxicity. König’s work has practical implications for improving patient outcomes in critical care and reducing antimicrobial resistance through precise dosing strategies. She collaborates with pharmacists and clinicians to enhance medication safety and evidence-based practices in acute care settings.